

## Special Issue

# ***Bordetella pertussis* Infection and Vaccination**

### Message from the Guest Editor

Pertussis or whooping cough is an acute infection of the respiratory tract caused by the bacterium *Bordetella pertussis* (Bp). Despite good vaccination coverage, it remains a disease with one of the highest residual morbidity and mortality, and it is especially dangerous for infants and young children. At present, not only is the number of pertussis cases increasing, but the Bp carriership in the human population also remains high. Several attempts have been made to improve current vaccination strategies, such as optimizing the composition of current acellular vaccines or testing alternative vaccination routes. This Special Issue of *Vaccines* focuses on research that aims to understand immune responses to Bp infection and vaccination, which can shed light on the high pertussis incidence and provide strategies for better pertussis management at the population level. Submissions to this Special Issue can be studies that either evaluate current pertussis vaccines or are aiming to improve them. Research in both human and animal models are welcome. Dr. Magdalena A. Berkowska

### Guest Editor

Dr. Magdalena A. Berkowska

Department of Immunology, Leiden University Medical Centre (LUMC),  
2333 ZA Leiden, The Netherlands

### Deadline for manuscript submissions

7 August 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/71960](https://mdpi.com/si/71960)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).